Hotchkis & Wiley Fund's Positive Outlook on Marriott Vacations Worldwide
Money

Hotchkis & Wiley Fund's Positive Outlook on Marriott Vacations Worldwide

authorBy Natalie Pace
DateAug 04, 2026
Read Time3 min
This report analyzes the Q2 2026 investor letter from Hotchkis & Wiley, focusing on their favorable assessment of Marriott Vacations Worldwide (VAC). The fund's perspective on VAC's market position, financial health, and future prospects is detailed, offering insights into its investment strategy.

Marriott Vacations: A Resilient Investment Amidst Market Dynamics

Hotchkis & Wiley's Q2 2026 Investment Review

Hotchkis & Wiley, a respected investment management company, recently published its investor letter for the second quarter of 2026 for the Hotchkis & Wiley Mid-Cap Value Fund. This period saw robust performance in equity markets, with the Russell Midcap Index climbing 13.8% and the Russell Midcap Value Index increasing by 13.4%. These gains occurred despite prevailing anxieties regarding inflation, a hawkish Federal Reserve, and rising oil prices stemming from geopolitical conflicts. Market leadership was concentrated, notably in semiconductor and artificial intelligence (AI) sectors, which recorded returns exceeding 100%. The firm, however, maintains its preference for high-quality businesses with attractive valuations, suggesting that concerns about AI's disruptive potential are exaggerated. The Hotchkis & Wiley Mid-Cap Value Fund returned 4.74% in Q2, trailing the Russell Midcap Value Index primarily due to underperformance in the technology and energy sectors, though strong stock selection in healthcare provided a positive offset.

Marriott Vacations Worldwide: A Standout Performer

In its Q2 2026 investor letter, the Hotchkis & Wiley Mid-Cap Value Fund specifically lauded Marriott Vacations Worldwide Corporation (NYSE: VAC). As a prominent vacation and timeshare ownership enterprise, VAC showcased impressive results during the quarter. By August 3, 2026, Marriott Vacations Worldwide Corporation's shares closed at $97.40, commanding a market capitalization of $3.34 billion. While the stock experienced a slight one-month decline of 1.96%, its shares surged by 33.46% over the preceding 52 weeks, indicating significant long-term growth.

Investment Rationale for Marriott Vacations Worldwide

Hotchkis & Wiley Mid-Cap Value Fund elaborated on its positive stance regarding Marriott Vacations Worldwide Corporation (NYSE: VAC) in its Q2 2026 investor letter. The firm views VAC as one of the largest timeshare operators in the U.S., engaged in the development, sale, financing, and management of upscale and luxury resorts under renowned brands like Marriott, Westin, Ritz-Carlton, and Hyatt. This is complemented by a highly profitable exchange business. Hotchkis & Wiley considers VAC a valuable, albeit sometimes misunderstood, company. Its established brand network, affluent customer base with an average net worth of approximately $1.5 million, and consistent revenue streams from financing and fees contribute to its resilience against the inherent cyclicality of the travel industry. VAC's stock outperformed expectations this quarter, driven by results surpassing low Street forecasts, management's affirmation of full-year guidance while enhancing its contract-sales outlook, and sustained robust free cash flow generation.

Broader Market Context and Alternative Investments

Despite the strong performance, Marriott Vacations Worldwide Corporation (NYSE: VAC) is not currently featured on Hotchkis & Wiley's list of the 40 Most Popular Stocks Among Hedge Funds heading into 2026. Data from the end of the first quarter revealed that 30 hedge fund portfolios held VAC, consistent with the prior quarter. While acknowledging VAC's investment potential, the firm suggests that certain AI stocks may offer greater upside and carry less downside risk. For investors seeking an exceptionally undervalued AI stock poised to benefit from current economic trends, specialized reports are available. Additionally, other analyses have referenced Marriott Vacations Worldwide Corporation in discussions about top stock picks by prominent investors and broader hedge fund investment letters for Q2 2026.

More Articles
Money
Navigating Major Home Repairs: Cash vs. Borrowing
Facing a significant home repair, a homeowner with a $27,000 emergency fund considers whether to deplete her savings or secure financing. Experts weigh in on the pros and cons of using cash versus borrowing, exploring options like high-yield savings accounts, home equity lines of credit (HELOCs), and the importance of consulting financial advisors and reviewing insurance policies to make an informed decision.
By Ramit SethiAug 04, 2026
Money
Prediction Market Rivals Vie for Billions: Polymarket vs. Kalshi
Polymarket is reportedly seeking a valuation of over $20 billion in its latest fundraising round, marking its second valuation increase in four months. This move comes as its competitor, Kalshi, recently secured a $22 billion valuation and is now aiming for a staggering $40 billion. The article highlights the intense competition and rapid growth within the prediction market sector, where both platforms are experiencing substantial increases in trading volume.
By T. Harv EkerAug 04, 2026
Money
Centene Corporation Reports Strong Earnings and Positive Outlook
Centene Corporation, a prominent healthcare provider, showcased robust financial performance in the second quarter of 2026, exceeding analyst expectations. The company's adjusted earnings per share significantly surpassed consensus estimates, leading to an upward revision of its full-year guidance. This strong showing is largely attributed to improved Medicaid margins and a successful recalibration of Affordable Care Act (ACA) memberships, signaling a positive trajectory for the firm in the evolving healthcare landscape.
By T. Harv EkerAug 04, 2026
Money
Elevance Health's Financial Rebound Anticipated in 2027
Greenskeeper Asset Management's Q2 2026 report highlights Elevance Health (ELV) as a significant contributor to their portfolio's performance. Despite a challenging period with elevated medical costs, ELV's profitability is expected to recover, driven by stabilized cost trends and favorable government reimbursement updates. The firm anticipates 2027 will mark a strong earnings recovery, building on ELV's robust commercial health insurance foundation.
By Natalie PaceAug 04, 2026
Money
Argenx SE Expands Vyvgart's Reach in Autoimmune Disease Treatment
Baron Capital's Q2 2026 investor letter highlights Argenx SE's progress with Vyvgart, an FcRn inhibitor. The company aims to demonstrate its efficacy across a wider spectrum of autoimmune conditions, showing promise in clinical trials and maintaining a strong pipeline. This development comes despite leadership changes, reinforcing investor confidence in its future growth.
By Vicki RobinAug 04, 2026